<DOC>
	<DOCNO>NCT02818998</DOCNO>
	<brief_summary>To evaluate efficacy long-term treatment 2 mg aflibercept via different intravitreal ( IVT ) treatment regimens subject DME pretreated 2 mg aflibercept every 8 week 5 initial monthly injection approximately 1 year ( accord EU label first year treatment )</brief_summary>
	<brief_title>Efficacy Safety Three Different Aflibercept Regimens Subjects With Diabetic Macular Edema ( DME )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>The subject 's history aflibercept treatment meet follow : 1 . Treatment study eye initiate five monthly ( 1 week /+2 week ) dose 2 mg aflibercept improvement visual anatomic outcome observe document . 2 . Following initiation phase , interval treatment 6 week 12 week ( one exception allow ) . 3 . The interval last two prestudy injection ≥ 8 week , visual anatomic outcome stable interval . 4 . The subject receive last IVT ( intravitreal ) injection aflibercept study eye 8 week ( ±10 day ) first plan treatment /randomization study . 5 . Total prior treatment duration aflibercept ( i.e . first aflibercept treatment ever enrollment study ) 1 year longer . To meet initiation prestudy aflibercept treatment : Type1 2 diabetes mellitus Diagnosis DME ( diabetic macular edema ) secondary diabetes mellitus involve center macula ( defined area center subfield OCT ) study eye Decrease vision determine primarily result DME study eye BCVA study eye ETDRS letter score 73 24 ( correspond Snellen equivalent approximately 20/40 20/320 ) At initiation prestudy aflibercept treatment : Previous treatment antiangiogenic drug study eye ( e.g . pegaptanib sodium , bevacizumab , ranibizumab aflibercept ) within last 12 week initiation aflibercept prestudy treatment At follow time point : ) Initiation prestudy aflibercept treatment ii ) Screening study iii ) Baseline study History vitreoretinal surgery and/or include scleral buckling study eye Prior treatment study eye Long acting steroid , either periocular intraocular , precede 120 day Iluvien intravitreal implant time Active proliferative diabetic retinopathy ( PDR ) , current iris neovascularization , vitreous hemorrhage , tractional retinal detachment study eye Cataract surgery within 90 day aflibercept treatment study eye Preretinal fibrosis involve macula study eye Structural damage center macula study eye likely preclude improvement BCVA follow resolution macular edema include atrophy retinal pigment epithelium , subretinal fibrosis scar , significant macular ischemia organize hard exudate Concurrent disease study eye , DME , could compromise VA ( visual acuity ) , require medical surgical intervention study period , could confound interpretation result ( include advance glaucoma , retinal vascular occlusion , retinal detachment , macular hole , choroidal neovascularization cause ) Administration systemic anti angiogenic agent within 180 day aflibercept treatment Uncontrolled diabetes mellitus define hemoglobin ( Hb ) A1c &gt; 12.0 % Uncontrolled blood pressure ( define systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 95 mmHg subject sit confirm two separate measurement ) At follow time point : ) Screening study ii ) Baseline study Any ocular periocular infection precede 4 week either eye Filtration surgery glaucoma past likely need future study eye Uncontrolled glaucoma ( defined intraocular pressure [ IOP ] &gt; 25 mmHg despite treatment antiglaucoma medication ) study eye History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render subject high risk treatment complication Significant medium opacity , include cataract , study eye interfere visual acuity , fundus photography OCT ( optical coherence tomography ) imaging .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>DME</keyword>
</DOC>